Last Updated on December 31, 2023 by The Health Master
Drug firm Lupin on Saturday said it has received approval from the US health regulator to market Sevelamer Carbonate for Oral Suspension, used in the control of serum phosphorus with chronic kidney disease (CKD) on dialysis.
The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Sevelamer Carbonate for Oral Suspension in the American market, Lupin said in a statement.
This product will be manufactured at the company’s Goa facility, it added.
As per IQVIA MAT September 2021 data, Sevelamer Carbonate for Oral Suspension had an estimated annual sales of $51.7 million in the US.
USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets
USFDA authorises first oral antiviral to treat COVID
USFDA approves expanded use of Amgen’s psoriasis drug
USFDA gives nod to Cipla for Lanreotide injection
USFDA gives Orphan Drug Designation to Zydus for malaria treatment
USFDA relaxes restriction on Abortion Pill
Side-Effect of Ibuprofen – Painful Skin Disorders: India to act soon
CDSCO panel weighing risks and benefits of Covid drug Molnupiravir
USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets
5 reasons why e-Rx (electronic prescription) is better than paper Rx
At-home COVID-19 rapid test gets ok from USFDA: Roche
Remdesivir drug should only be used in patients with ‘moderate to…
Schedule for 19 FDCs permitted pre-1988 to give online presentation
Drug alert: 22 out of 1102 samples declared as NSQ in…
Haryana is the best state for setting up Pharma Industries: HM
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
